Related Experiment Video

Updated: May 19, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
08:21

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

The future of warfarin pharmacogenetics in under-represented minority groups

Larisa H Cavallari1, Minoli A Perera

  • 1Department of Pharmacy Practice, University of Illinois at Chicago, College of Pharmacy, 833 South Wood Street, Chicago, IL 60612-7230, USA. humma@uic.edu

Future Cardiology
|August 9, 2012
PubMed

Insights

Genotype-guided warfarin dosing needs adjustments for African-Americans. Genetic variants common in this population significantly impact warfarin dose requirements, unlike in Caucasian and Hispanic populations.

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Genetics

Background:

  • US FDA-approved warfarin labeling includes genotype-based dosing recommendations.
  • These recommendations were primarily informed by data from Caucasian populations.
  • Genetic variants influencing warfarin dose show differing impacts across racial groups.

Purpose of the Study:

  • To evaluate the influence of genetic variants on warfarin dosing in African-Americans.
  • To determine the applicability of Caucasian-based genotype-guided warfarin dosing in African-Americans.
  • To highlight the need for population-specific genetic considerations in warfarin pharmacogenomics.

Main Methods:

  • Analysis of genetic variants affecting warfarin metabolism and response.
  • Comparison of variant contributions to warfarin dose requirements across different racial groups.
  • Review of existing warfarin dosing guidelines and supporting data.

Main Results:

  • Warfarin dose-influencing variants in Caucasians have similar effects in US Hispanics.
  • These variants have lesser contributions to warfarin dose requirements in African-Americans.
  • Genetic variants prevalent in individuals of African ancestry significantly affect warfarin dosing in African-Americans.

Conclusions:

  • Genotype-guided warfarin dosing requires consideration of variants specific to African-Americans.
  • Current FDA-approved warfarin labeling may not be optimal for African-Americans due to population-specific genetic differences.
  • Implementing genotype-guided warfarin therapy in African-Americans necessitates incorporating relevant genetic markers for this population.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...